<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03933787</url>
  </required_header>
  <id_info>
    <org_study_id>2018-00569</org_study_id>
    <nct_id>NCT03933787</nct_id>
  </id_info>
  <brief_title>Neuropeptide Y and Sympathovagal Balance</brief_title>
  <acronym>NPY</acronym>
  <official_title>Neuropeptide Y Function in the Sympathovagal Balance During an Ergometric Test in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eric Grouzmann</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>grégoire wuerzner</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>grégoire millet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nicolas Bourdillon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philippe Eugster</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuropeptide Y (NPY) activates the sympathetic and vagal nervous systems through the Y1 and
      Y2 receptors. This double-blind placebo-controlled crossover study investigated the
      sympathovagal balance during three exercises on a cycloergometer in healthy volunteers
      treated with saxagliptin (DPP4 inhibitor).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacological studies indicate that NPY has a role as a co-transmitter associated with
      catecholamines to maintain cardiovascular homeostasis. The development of a selective and
      sensitive assay of NPY1-36 (vasoconstrictor) and NPY3-36 (vasodilator) by LC-MS/MS will
      confirm this modulating role of NPY in sympatho vagal balance in healthy young subjects. This
      project should lead to a better understanding of the contribution of NPY to exercise
      physiology through a double-blind randomized study using a DPP4 inhibitor (Saxagliptin) used
      for the treatment of type 2 diabetes, blocking the formation of NPY3-36 and thus enhancing
      the effect of NPY1-36. The interest of this study will be to find targets other than
      adrenergic receptors in the regulation of sympathetic and parasympathetic systems during
      exercise.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 5, 2018</start_date>
  <completion_date type="Actual">April 15, 2019</completion_date>
  <primary_completion_date type="Actual">July 18, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>double-blind placebo-controlled crossover study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The participants, investigator and care provider were not aware when the placebo or Saxagliptin was provided. The biochemical assays were performed in a random order with anonymised sample numbers. The data were analysed before revealing to which session each participant received the placebo or Sitagliptin</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rate change variability assessed at the end of each exercise</measure>
    <time_frame>5 hours and 30 minutes</time_frame>
    <description>RMSSD (Root mean square of successive RR interval differences) measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate change variability assessed at the end of each exercise</measure>
    <time_frame>5 hours and 30 minutes</time_frame>
    <description>normalized low frequency (nLF) measurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NPY 1-36 secretion</measure>
    <time_frame>5 hours and 30 minutes</time_frame>
    <description>half-life [t1/2]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPY 1-36 secretion</measure>
    <time_frame>5 hours and 30 minutes</time_frame>
    <description>Area under the plasma concentration versus time curve [AUC]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPY 1-36 secretion</measure>
    <time_frame>5 hours and 30 minutes</time_frame>
    <description>Peak Plasma Concentration [Cmax]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPY 3-36 secretion</measure>
    <time_frame>5 hours and 30 minutes</time_frame>
    <description>Half-life [t1/2]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPY3-36 secretion</measure>
    <time_frame>5 hours and 30 minutes</time_frame>
    <description>Area under the plasma concentration versus time curve [AUC]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPY3-36 secretion</measure>
    <time_frame>5 hours and 30 minutes</time_frame>
    <description>Peak Plasma Concentration [Cmax]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catecholamine secretion</measure>
    <time_frame>5 hours and 30 minutes</time_frame>
    <description>Half-life [t1/2]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catecholamine secretion</measure>
    <time_frame>5 hours and 30 minutes</time_frame>
    <description>Area under the plasma concentration versus time curve [AUC]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catecholamine secretion</measure>
    <time_frame>5 hours and 30 minutes</time_frame>
    <description>Peak Plasma Concentration [Cmax]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Physical Activity</condition>
  <condition>Sympathetic Nervous System</condition>
  <condition>Secretion; Catecholamine</condition>
  <arm_group>
    <arm_group_label>mannitol in a tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>two tablets containing mannitol in a blister: one tablet provided to each volunteer in a blister 16 hours before the trial and one tablet provided two hours before the clinical trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin in a tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>two tablets containing each 5 mg of Saxagliptin in a blister: one tablet provided to each volunteer in a blister 16 hours before the trial and one tablet provided two hours before the clinical trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin 5mg</intervention_name>
    <description>Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin</description>
    <arm_group_label>Saxagliptin in a tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin</description>
    <arm_group_label>mannitol in a tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ergometric test in healthy volunteers</intervention_name>
    <description>The volunteers will undergo an ergometric test in each session</description>
    <arm_group_label>Saxagliptin in a tablet</arm_group_label>
    <arm_group_label>mannitol in a tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male subjects aged between 18 and 30 years.

          2. Non smoking

          3. Practicing at least 3 hours physical activity per week

          4. Absence of significant findings in the medical history and physical examination as
             judged by the Investigator, especially for cardiovascular, pulmonary, haematological
             and nervous systems

          5. Ability to understand the procedures, agreement to participate and willingness to give
             written informed consent

          6. Co-operative attitude and availability for scheduled visits over the entire study
             period.

        Exclusion Criteria:

          1. Use of any medication the week prior to study. Paracetamol is permissible before and
             during study as a concomitant medication but only with Investigator's permission.

          2. History of major cardiovascular, pulmonary, hepatic, immunological, renal,
             haematological, gastrointestinal, genitourinary, neurological, or rheumatologic
             disorders

          3. rhinosinusitis

          4. Urinary tract infection

          5. Hypertension defined as supine blood pressure &gt;150/90 mmHg or recurrent hypotensive
             events considered as clinically relevant or documented orthostatic hypotension
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Grouzmann, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Néphrologie</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 19, 2019</study_first_submitted>
  <study_first_submitted_qc>April 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Eric Grouzmann</investigator_full_name>
    <investigator_title>Head of laboratory</investigator_title>
  </responsible_party>
  <keyword>neuropeptide Y,catecholamine, exercise</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>all IPD that underlie results in a publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

